Emergency Medicine Cases – Where the Experts Keep You in the Know. For complete episodes please visit emergencymedicinecases.com
Caron Jacobson, MD - Unlocking the Benefits of CAR-T Therapy in Hematologic Malignancies: Latest Evidence and Practical Considerations for Delivering State-of-the-Art Care
Manage episode 348511965 series 1058605
By PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/XZA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This unique video-based activity will offer learners a window into practice by featuring a series of expert-led lectures that will seamlessly link the latest scientific evidence on CAR-T therapy across a range of hematologic malignancies with panel-based insights on clinical decision-making. Each session will include a Tumor Board segment designed to reflect real-world clinical experiences and decision challenges, from identifying patient candidates to appropriate follow-up and the management of a unique spectrum of adverse events. Upon completion of this CE activity, participants will be able to: Evaluate the latest clinical evidence on the safety and efficacy of chimeric antigen receptor (CAR)-T cell therapies in patients with hematological malignancies across existing and potential future indications; Adopt best practices for integrating CAR-T therapy into the care of patients with hematologic malignancies, including appropriate patient selection, referral to specialized treatment centers, clinical trial enrollment, and provision of post-treatment follow-up care; and Develop appropriate adverse event management strategies for patients with hematological malignancies who are experiencing toxicity (eg, cytokine release syndrome or neurotoxicity) while receiving CAR-T therapy.